ResMed Inc. (NYSE:RMD) Stake Lifted by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its stake in ResMed Inc. (NYSE:RMD) by 8.0% in the 4th quarter, HoldingsChannel reports. The fund owned 13,454 shares of the medical equipment provider’s stock after acquiring an additional 993 shares during the period. Daiwa Securities Group Inc.’s holdings in ResMed were worth $2,314,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Ossiam boosted its holdings in shares of ResMed by 2.4% in the first quarter. Ossiam now owns 1,919 shares of the medical equipment provider’s stock valued at $420,000 after acquiring an additional 45 shares in the last quarter. Ascent Group LLC boosted its holdings in shares of ResMed by 2.3% in the third quarter. Ascent Group LLC now owns 1,995 shares of the medical equipment provider’s stock valued at $446,000 after acquiring an additional 45 shares in the last quarter. SeaCrest Wealth Management LLC boosted its holdings in shares of ResMed by 3.6% in the fourth quarter. SeaCrest Wealth Management LLC now owns 1,400 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 48 shares in the last quarter. Capital Impact Advisors LLC boosted its holdings in shares of ResMed by 3.0% in the fourth quarter. Capital Impact Advisors LLC now owns 1,916 shares of the medical equipment provider’s stock valued at $399,000 after acquiring an additional 56 shares in the last quarter. Finally, Dearborn Partners LLC boosted its holdings in shares of ResMed by 3.8% in the third quarter. Dearborn Partners LLC now owns 1,577 shares of the medical equipment provider’s stock valued at $344,000 after acquiring an additional 57 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the stock. JPMorgan Chase & Co. increased their target price on shares of ResMed from $160.00 to $195.00 and gave the company an “overweight” rating in a research note on Tuesday, January 9th. Oppenheimer increased their target price on shares of ResMed from $185.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Royal Bank of Canada increased their target price on shares of ResMed from $181.00 to $182.00 and gave the company a “sector perform” rating in a research note on Thursday, January 25th. KeyCorp assumed coverage on shares of ResMed in a research note on Tuesday, February 6th. They set an “overweight” rating and a $227.00 target price for the company. Finally, Mizuho reissued a “buy” rating and set a $215.00 target price on shares of ResMed in a research note on Wednesday, March 27th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $199.20.

ResMed Trading Up 0.7 %

ResMed stock opened at $178.85 on Monday. The company has a 50 day moving average price of $186.18 and a 200 day moving average price of $170.79. The firm has a market capitalization of $26.31 billion, a price-to-earnings ratio of 29.56, a P/E/G ratio of 2.19 and a beta of 0.67. ResMed Inc. has a 52 week low of $132.24 and a 52 week high of $243.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.89 and a current ratio of 3.11.

ResMed (NYSE:RMD) last issued its earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.81 by $0.07. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.15 billion. ResMed had a net margin of 19.77% and a return on equity of 23.86%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the business posted $1.66 EPS. Research analysts forecast that ResMed Inc. will post 7.47 EPS for the current year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Shareholders of record on Thursday, February 8th were paid a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 1.07%. The ex-dividend date of this dividend was Wednesday, February 7th. ResMed’s dividend payout ratio (DPR) is currently 31.74%.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the completion of the sale, the director now owns 157,404 shares of the company’s stock, valued at approximately $28,751,414.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the transaction, the general counsel now owns 6,688 shares in the company, valued at approximately $1,158,696. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 10,935 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the transaction, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. Insiders sold 11,216 shares of company stock valued at $2,046,617 in the last quarter. Company insiders own 1.21% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.